Prelude Therapeutics (PRLD) Operating Leases (2021 - 2026)

Prelude Therapeutics has disclosed Operating Leases across 6 years of filings, most recently posting $15.0 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $15.0 million, down 2.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.0 million (down 2.01% YoY), and the FY2025 annual result was $15.0 million, down 1.83% from the prior year.
• Operating Leases came in at $15.0 million for Q1 2026 at Prelude Therapeutics, down from $15.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $18.1 million in Q3 2024 to a low of $390000.0 in Q1 2022.
• The 5-year median for Operating Leases is $15.3 million (2025), against an average of $14.2 million.
• Across the five-year window, Operating Leases slumped 53.57% in 2022 and declined 0.53% in 2024, its largest moves.
• Prelude Therapeutics' Operating Leases stood at $390000.0 in 2022, then surged by 3850.51% to $15.4 million in 2023, then dropped by 0.53% to $15.3 million in 2024, then declined by 1.83% to $15.0 million in 2025, then fell by 0.56% to $15.0 million in 2026.
• The last three Operating Leases figures came in at $15.0 million (Q1 2026), $15.0 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.